BioAge Labs Announces First Participant Dosed In Phase 1 Clinical Trial Evaluating BGE-102, Orally Available Small Molecule NLRP3 Inhibitor For Treatment Of Obesity

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

Initial development planned in obesity; BGE-102 demonstrated robust weight loss in preclinical models, both as monotherapy and in combination with GLP-1 receptor agonists

Initial Phase 1 SAD data anticipated by end of 2025, with top-line readout of obesity study by end of 2026

EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in a Phase 1 clinical trial evaluating BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration being developed initially for the treatment of obesity.